A narrative review on adverse drug reactions of COVID-19 treatments on the kidney
F Jahanshahi, SB Jazayeri, MM Eraghi, LO Reis… - Open …, 2024 - degruyter.com
Studies showed that the respiratory is not the only system affected by coronavirus 2, while
cardiovascular, digestive, and nervous systems, as well as essential organs such as the …
cardiovascular, digestive, and nervous systems, as well as essential organs such as the …
[HTML][HTML] COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment
AD Elec, M Oltean, P Goldis, C Cismaru… - International Journal of …, 2021 - Elsevier
Objectives The lack of effective treatments for coronavirus disease 2019 (COVID-19) has
mandated the repurposing of several drugs, including antiretrovirals and remdesivir (RDV) …
mandated the repurposing of several drugs, including antiretrovirals and remdesivir (RDV) …
Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real …
X Chen, Y Zhu, L Shen, D Zhou… - Journal of Intensive …, 2024 - journals.sagepub.com
Background: Nirmatrelvir/Ritonavir is an orally administered anti-SARS-Cov-2 drug used in
mild-to-moderate COVID-19 patients. Our retrospective cohort study aims to evaluate the …
mild-to-moderate COVID-19 patients. Our retrospective cohort study aims to evaluate the …
[引用][C] Kami nska, D. Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney …
H Augustyniak-Bartosik, A Magiera-Zak, K Skalec… - 2022 - europepmc.org
Background: Molnupiravir demonstrated an in vitro antiviral activity against positivesense
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID‐19 in clinical practice during the Omicron (BA. 1 and BA. 2) pandemic
K Kikuchi, M Nangaku, M Ryuzaki… - Therapeutic …, 2023 - Wiley Online Library
Introduction In the present study, the efficacy of sotrovimab and molnupiravir in dialysis
patients with COVID‐19 was investigated using a registry of COVID‐19 in Japanese dialysis …
patients with COVID‐19 was investigated using a registry of COVID‐19 in Japanese dialysis …
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a …
T Sakaguchi, A Mitsuke, Y Osako, Y Yamada… - BMC nephrology, 2024 - Springer
Abstract Background Kidney transplant recipients (KTRs) are at risk of severe coronavirus
disease 2019 (COVID-19), and even now that Omicron subvariants have become dominant …
disease 2019 (COVID-19), and even now that Omicron subvariants have become dominant …
Kidney disease and COVID-19 disease severity—systematic review and meta-analysis
We aimed to identify prevalence and association of comorbid chronic kidney disease (CKD),
acute kidney injury (AKI) and utilization prevalence of continuous renal replacement therapy …
acute kidney injury (AKI) and utilization prevalence of continuous renal replacement therapy …
The impact of COVID-19 infection before the vaccination era on the hospitalized patients requiring hemodialysis: a single-center retrospective cohort
ÁG Pethő, P Kevei, M Juha, Á Kóczy, N Ledó… - Renal …, 2023 - Taylor & Francis
Due to effective vaccinations, the COVID-19 (coronavirus disease 2019) infection that
caused the pandemic has a milder clinical course. We aimed to assess the mortality of …
caused the pandemic has a milder clinical course. We aimed to assess the mortality of …
[HTML][HTML] Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: A retrospective multicenter study
F Stancampiano, N Jhawar, W Alsafi, J Valery… - Clinical Infection in …, 2022 - Elsevier
Background and objectives Remdesivir, an antiviral drug routinely used in the treatment of
COVID-19 has not yet received FDA approval for use in patients with advanced kidney …
COVID-19 has not yet received FDA approval for use in patients with advanced kidney …
AKI with COVID-19 Infection due to Drug Interaction of Tacrolimus and Nirmatrelvir/Ritonavir: PUB363
E jeong Ko, CW Yang - Journal of the American Society of …, 2023 - journals.lww.com
Background: The mortality of SARS-CoV-2 infection of kidney transplant recipients (KTR) is
higher than that of general population. Nirmatrelvir (NR) is a good option for outpatient …
higher than that of general population. Nirmatrelvir (NR) is a good option for outpatient …